| Trial ID: | L1788 |
| Source ID: | NCT02981966
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02981966/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Endogenous Glucose Production Measurement, Endogenous Glucose Production in NGT/T2DM subjects before and after dapagliflozin/Placebo administration from baseline to 240 minutes., 3 weeks | Secondary: Renal Glucose Production Measurement of Change, Renal Glucose Production in T2DM and NGT subjects before and after dapagliflozin/placebo administration from baseline to 240 minutes., Baseline to 3 weeks
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-05-23
|
| Completion Date: |
2023-05-31
|
| Results First Posted: |
2023-06-06
|
| Last Update Posted: |
2024-03-04
|
| Locations: |
University of Texas Health Science Center, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02981966
|
